• Tenaya Therapeutics Inc TNYA.OQ reported a quarterly adjusted loss of 12 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -28 cents. The mean expectation of eight analysts for the quarter was for a loss of 12 cents per share. Wall Street expected results to range from -17 cents to -10 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Tenaya Therapeutics Inc's reported EPS for the quarter was a loss of 12 cents​.

• The company reported a quarterly loss of $20.18 million.

• Tenaya Therapeutics Inc shares had risen by 25.8% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 18.5% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Tenaya Therapeutics Inc is $3.00, about 70.2% above its last closing price of $0.90

This summary was machine generated from LSEG data March 11 at 08:55 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)